Currently, the most robust study involving imatinib-naïve GIST patients, 10 (mostly localized tumors) out of 529 GISTs harbored PIK3CA mutations, which were associated with larger and aggressive tumors [88] ]. This evidence concerns the gene PIK3CA and gastrointestinal stromal tumor.